119 related articles for article (PubMed ID: 31982182)
1. Clinical and pathological characteristics of bladder cancer in post brachytherapy patients.
Au S; Keyes M; Black P; Villamil CF; Tavassoli P
Pathol Res Pract; 2020 Mar; 216(3):152822. PubMed ID: 31982182
[TBL] [Abstract][Full Text] [Related]
2. Invasive bladder cancer following 125iodine implants.
Winters JC; Fuselier HA
J Urol; 1992 Dec; 148(6):1898-900. PubMed ID: 1433634
[TBL] [Abstract][Full Text] [Related]
3. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
4. Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer.
Chin CP; Smith WH; Cesaretti J; Terk M; Garden EB; Araya JS; Palese MA; Stock RG; Buckstein M
Urol Oncol; 2023 Jun; 41(6):296.e9-296.e16. PubMed ID: 36588020
[TBL] [Abstract][Full Text] [Related]
5. Urothelial carcinoma after external beam radiation therapy for prostate cancer.
Shah SK; Lui PD; Baldwin DD; Ruckle HC
J Urol; 2006 Jun; 175(6):2063-6. PubMed ID: 16697804
[TBL] [Abstract][Full Text] [Related]
6. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
7. The characteristics of bladder cancer after radiotherapy for prostate cancer.
Abern MR; Dude AM; Tsivian M; Coogan CL
Urol Oncol; 2013 Nov; 31(8):1628-34. PubMed ID: 22575239
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
[TBL] [Abstract][Full Text] [Related]
9. Secondary mucinous carcinoma of the prostate after low dose rate brachytherapy.
Murchison SC; Martens MB; Truong P; Alexander A
Can J Urol; 2018 Apr; 25(2):9284-9287. PubMed ID: 29680008
[TBL] [Abstract][Full Text] [Related]
10. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
Gordetsky J; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
[TBL] [Abstract][Full Text] [Related]
11. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
[TBL] [Abstract][Full Text] [Related]
12. Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6.
Johnson SM; Khararjian A; Legesse TB; Khani F; Robinson BD; Epstein JI; Wobker SE
Am J Clin Pathol; 2021 Mar; 155(4):588-596. PubMed ID: 33118597
[TBL] [Abstract][Full Text] [Related]
13. Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer.
Musunuru H; Mason M; Murray L; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D; Henry AM
Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):210-5. PubMed ID: 24507938
[TBL] [Abstract][Full Text] [Related]
14. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
15. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
[TBL] [Abstract][Full Text] [Related]
16. The risk of second malignancies after
Fernandez Ots A; Browne L; Chin YS; Malouf D; Wong K; Bucci J
Brachytherapy; 2016; 15(6):752-759. PubMed ID: 27475483
[TBL] [Abstract][Full Text] [Related]
17. Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy.
Raleigh DR; Hsu IC; Braunstein S; Chang AJ; Simko JP; Roach M
Brachytherapy; 2015; 14(2):185-8. PubMed ID: 25533416
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
[TBL] [Abstract][Full Text] [Related]
19. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases.
Wang G; Xiao L; Zhang M; Kamat AM; Siefker-Radtke A; Dinney CP; Czerniak B; Guo CC
Hum Pathol; 2018 Sep; 79():57-65. PubMed ID: 29763719
[TBL] [Abstract][Full Text] [Related]
20. Radical cystectomy in patients previously treated for localized prostate cancer.
Jayram G; Katz MH; Steinberg GD
Urology; 2010 Dec; 76(6):1430-3. PubMed ID: 20381130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]